Principal Financial Group Inc. Has $4.78 Million Holdings in BioLife Solutions, Inc. (NASDAQ:BLFS)

Principal Financial Group Inc. boosted its position in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 4.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 190,715 shares of the medical equipment provider’s stock after acquiring an additional 8,580 shares during the period. Principal Financial Group Inc. owned 0.41% of BioLife Solutions worth $4,776,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Stifel Financial Corp lifted its position in shares of BioLife Solutions by 5.4% during the 3rd quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock worth $325,000 after purchasing an additional 670 shares during the last quarter. GAMMA Investing LLC increased its position in BioLife Solutions by 29.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock worth $83,000 after buying an additional 748 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in shares of BioLife Solutions by 5.8% during the second quarter. The Manufacturers Life Insurance Company now owns 13,825 shares of the medical equipment provider’s stock worth $296,000 after buying an additional 753 shares during the last quarter. Mark Sheptoff Financial Planning LLC bought a new stake in shares of BioLife Solutions in the third quarter valued at approximately $28,000. Finally, Curi RMB Capital LLC grew its stake in shares of BioLife Solutions by 0.5% in the third quarter. Curi RMB Capital LLC now owns 421,933 shares of the medical equipment provider’s stock worth $10,565,000 after acquiring an additional 2,283 shares during the last quarter. 93.24% of the stock is currently owned by institutional investors.

Insider Buying and Selling at BioLife Solutions

In other BioLife Solutions news, EVP Aby J. Mathew sold 25,000 shares of the business’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $21.17, for a total value of $529,250.00. Following the transaction, the executive vice president now directly owns 302,046 shares in the company, valued at $6,394,313.82. The trade was a 7.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 64,259 shares of company stock worth $1,424,708 over the last three months. Company insiders own 2.20% of the company’s stock.

BioLife Solutions Trading Up 0.8 %

BLFS stock opened at $26.18 on Friday. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The firm has a market cap of $1.21 billion, a P/E ratio of -24.70 and a beta of 1.91. BioLife Solutions, Inc. has a 1-year low of $14.50 and a 1-year high of $28.88. The business’s 50 day moving average is $25.59 and its 200-day moving average is $24.06.

Wall Street Analyst Weigh In

Several research firms recently commented on BLFS. KeyCorp upped their target price on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. Craig Hallum increased their target price on shares of BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. HC Wainwright lowered their price target on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. TD Cowen raised their price objective on BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Finally, Benchmark restated a “buy” rating and set a $30.00 price objective on shares of BioLife Solutions in a research report on Thursday, December 19th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, BioLife Solutions has an average rating of “Moderate Buy” and a consensus price target of $29.00.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.